Leucadia Pharmaceuticals, the commercial sales unit of Custopharm, has launched the FDA-approved Sodium Tetradecyl Sulfate (STS) generic injection in the US.
According to Leucadia Pharmaceuticals, the regulated sclerosing agent is therapeutically equivalent to SOTRADECOL and is an effective and safe alternative to the use of unapproved compounded products.
Sodium Tetradecyl Sulfate is used for the treatment of small varicose veins of the lower legs.
Dr. William Larkins – CEO of Custopharm said: “For years patients have had no good options when seeking an affordable generic alternative to Sotradecol.
“As a result, some have turned to compounding pharmacies. Instead of finding a lower cost product they have been met with a ‘Wild West’ of unapproved and unregulated options which can present significant additional risk with no commensurate benefit. Leucadia’s FDA-approved STS now provides a safer alternative while also giving health care providers and health care systems peace of mind.”